Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes.

Zolinza (vorinostat) - Merck (MSD)

Zorifer (zorifertinib) - Alpha Biopharma, AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/41865932

Chunlan Ning; Jiaqi Zhou; Wenbin Jia; Xin Wang; Xuchen Cao; Yaoyao Zhou; Yongjine Xie; Yue Yu; Zewei Zhao

Mar 25, 2026